ArticleFrontiers in immunology2025
Comparison of SARS-CoV-2 immune responses following vaccination with Comirnaty (Pfizer) and Vaxzevria (AstraZeneca) in healthy individuals with or without prior SARS-CoV-2 infection.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Longitudinal study of the immunological response to the SARS-CoV-2 vaccine in Instituto Português de Oncologia of Coimbra professionals.IJID regions · 2026Article
- IL-10- and IL-13-Biased T Cell Responses to SARS-CoV-2 Vaccination in Diabetes.European journal of immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: This study compares the immune responses of healthy individuals, with or without prior SARS-CoV-2 infection, following vaccination with Comirnaty (Pfizer) and Vaxzevria (AstraZeneca). Methods: A total of 134 volunteers were analyzed: 71 recipients of Comirnaty (36 with prior infection) and 63 recipients of Vaxzevria (33 with prior infection). Immune responses were assessed after the second and third doses by measuring anti-SARS-CoV-2 IgG levels and interferon-gamma (IFN-γ) production using an IGRA assay. Results: Significant differences were observed in IgG and IFN-γ concentrations between the vaccine groups. Higher IgG and IFN-γ levels were noted in individuals vaccinated with Comirnaty, especially after the third dose, indicating a stronger T-cell-mediated response. Prior infection enhanced immune responses, as previously infected individuals showed elevated IgG and IFN-γ levels. Hematological analysis revealed differences in immune activation patterns between vaccines, including variations in white blood cell counts, neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR). Discussion: These findings highlight distinct vaccine-induced immune responses depending on vaccine type, prior infection status, and number of doses administered. They contribute to understanding the differential immune memory elicited by mRNA-based and adenoviral vector-based vaccines and emphasize the importance of booster doses in maintaining robust immunity against SARS-CoV-2.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.